Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Imitrex(R) Tablets
Date:8/11/2009

DETROIT, Aug. 11 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched sumatriptan succinate tablets on behalf of Sun Pharmaceutical Industries Ltd. (Sun Pharma), immediately following Sun Pharma's recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Imitrex(R) tablets. These sumatriptan succinate tablets, 25 mg (base), 50 mg (base) and 100 mg (base) are therapeutically equivalent to Imitrex(R) tablets from GlaxoSmithKline. Sumatriptan succinate tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.

Imitrex(R) is a registered trademark of GlaxoSmithKline.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE ... Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, California, who will ... Administration at St. Thomas University in Miami, Florida, was selected from a pool ...
(Date:9/22/2017)... HOUSTON, Texas (PRWEB) , ... September 22, 2017 ... ... leading network of independent freestanding emergency rooms is celebrating the one year anniversary ... anniversary of our facility opening,” said Dr. Otinwa, Facility Medical Director of First ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... products at customers’ doorstep. According to Smart Mart, customers can now order vegetable, ... offer wearable, and customers can find clothing at discounted prices. Apart from this, ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality ... run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves staring ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... in their communities, nine governmental public health departments have been awarded five-year accreditation ... decisions mean that the benefits of being served by a PHAB-accredited health ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... Sept. 13, 2017   OrthoAtlanta has been named ... Football Host Committee (AFHC) for the 2018 College Football Playoff ... 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... AFHC "I,m In" campaign, participating in many activities leading up ... ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology: